• Company to Host In-Person Event at ASH 2026 Featuring New Market Research and a Physician Panel Discussion on Barriers to CAR T Access, Community Adoption in Large B-Cell Lymphoma (LBCL), and the Potential Role of Cemacabtagene Ansegedleucel (Cema-cel) to Expand Patient Access
  • New Market Research Findings to be Published in a Supplement to Blood in Conjunction with the ASH Annual Meeting
  • ALPHA3, the First Registrational Trial Evaluating Minimal Residual Disease (MRD)-Guided First-Line Consolidation with Cema-cel, to Be Featured at Natera-Hosted Clinical Trial Showcase

SOUTH SAN FRANCISCO, Calif., Nov. 20, 2026 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced its participation in the 68th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans. Allogene’s activities at ASH will highlight the potential of allogeneic CAR T to expand patient access through new physician market research and expert discussions on barriers to treatment. Additionally, the Company’s pivotal ALPHA3 trial, evaluating cemacabtagene ansegedleucel (cema-cel) as minimal residual disease (MRD)-guided first-line consolidation therapy for patients with large B-cell lymphoma (LBCL), will be featured at a clinical trial showcase hosted by Natera.

“For too long, we’ve allowed the realities of the autologous CAR T delivery model to limit our vision of what’s possible,” said Zachary Roberts, M.D., Ph.D., President and Chief Executive Officer of Allogene Therapeutics. “The time has come to change that. Our new physician research points to an opportunity that extends beyond overcoming today’s stubborn access barriers. When physicians have an actionable treatment option, their willingness to test for MRD increases. When CAR T can potentially be delivered closer to patients, doors may open to broader adoption. With cema-cel and ALPHA3, we are pursuing both – bringing CAR T earlier in the treatment journey and potentially expanding where patients can receive it. At ASH, we want to challenge the industry to think bigger about what CAR T can become.”

COMPANY EVENT

CAR T for Real Life – Fixing What’s Broken with CAR T
Allogene will host an in-person event challenging conventional assumptions about when, where, and how CAR T can be delivered. The program will feature new market research from a survey of 152 hematologists and oncologists as well as a moderated panel of physicians to challenge current assumptions about CAR T delivery, explore the potential of MRD-guided intervention and community-based treatment, and discuss what it will take to translate these opportunities into clinical practice. The discussion will include a live audience Q&A.

The research abstract will be published in a supplement to Blood in conjunction with ASH 2026. The event is open to physicians, investors, and members of the media, with a live webcast available for those unable to attend in person.

  • Date/Time: Sunday, December 13, 2026, 8:00-9:00 a.m. CT
  • Format: In-person event featuring a moderated physician panel and live audience Q&A.
  • Listen-Only Webcast: Available live and on-demand at www.allogene.com under the Investors tab in the News and Events section. A replay will be available for approximately 30 days.
  • Event Registration: Click here to access

CLINICAL TRIAL SHOWCASE

ALPHA3: Pioneering MRD-Guided First-Line Consolidation in LBCL with Cema-Cel, an Allogeneic CAR T Built for Real-World Treatment

A Natera-hosted presentation will highlight the design and rationale of ALPHA3, the first registrational trial evaluating MRD-guided 1L consolidation in LBCL. The pivotal trial uses Natera’s patented phased variant technology to detect MRD after first line therapy. It evaluates cema-cel in patients who achieve remission following standard chemoimmunotherapy but remain at high risk of relapse, as identified by Natera’s CLARITY™ MRD assay.

  • Date/Time: Saturday, December 12, 2026, 3:45-4:00 p.m. CT
  • Host: David Kurtz, M.D., Ph.D., Natera, Inc.
  • Location: Ernest N. Morial Convention Center, New Orleans – Hall J – Corporate Presentation Theater 6

About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by cell therapy veterans applying proven CAR T experience, Allogene is developing a pipeline of off-the-shelf CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow Allogene Therapeutics on X and LinkedIn.

Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, Allogene’s ability to develop and deliver readily available allogeneic CAR T products for the treatment of cancer and autoimmune disease on-demand, more reliably, and at greater scale to more patients; the potential of allogeneic CAR T to expand patient access or address barriers to treatment; the potential for cema-cel to provide an actionable treatment option following MRD testing; the potential to increase physician willingness to test for MRD; the potential to deliver CAR T closer to where patients are located; the potential for broader adoption of CAR T; the potential to bring CAR T earlier in the treatment journey and to expand where patients can receive it; and the design and conduct of the ALPHA3 trial. Various factors may cause material differences between Allogene’s expectations and actual results, including risks and uncertainties related to: MRD testing and its clinical significance, including whether MRD-guided treatment will translate into clinically meaningful benefit; clinical development and enrollment in the ALPHA3 trial, including that interim or early data may not be predictive of final results; Allogene’s reliance on Natera for access to the CLARITY™ MRD assay, and whether an approved MRD assay will be commercially available if cema-cel is approved; whether cema-cel, if approved, will achieve market acceptance among physicians, including in community settings; and the risk that physician market research findings may not be predictive of actual physician behavior or market adoption. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the “Risk Factors” heading in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.

Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com

Leslie Bryant
Executive Director, Corporate Communications
Leslie.Bryant@allogene.com

AUSTIN, Texas, Nov. 20, 2026 (GLOBE NEWSWIRE) — Asure Software, Inc. (Nasdaq: ASUR) today announced that the number of job applications submitted to employers through Asure Recruiting is on track to exceed a record 1 million in 2026 and that its HR consulting engagements have continued to increase in 2026. Asure announced the milestones as it celebrates the independent businesses honored on Small Business Saturday, Nov. 28.

Recruiting software and HR consulting give Asure two ways to help employers beyond payroll. Employers can manage job postings and applications through Asure Recruiting and turn to Asure’s HR consultants for help with workplace policies and compliance. Asure serves more than 100,000 clients across the United States, both directly and through reseller partners.

Hiring remains active across the economy. According to the U.S. Bureau of Labor Statistics (BLS) Employment Situation report released Nov. 6, private-sector employers added 159,000 jobs in October, the latest month available, and total nonfarm payroll employment rose by 165,000. Private-sector job gains have averaged 126,000 per month over the past three months, and the unemployment rate was 4.1%.

“When an independent business owner, like those celebrated on Small Business Saturday, needs to hire, every hour spent sorting applications is an hour away from running the business,” said Pat Goepel, Chairman and CEO of Asure Software. “We help owners manage hiring and get practical HR advice when they need it. That’s how we can do more for the employers who already count on us for payroll.”

American Express founded Small Business Saturday in 2010, and the U.S. Small Business Administration has co-sponsored it since 2011. According to an American Express consumer survey cited by the SBA, shoppers spent an estimated $18 billion at local merchants on Small Business Saturday in 2025.

About Asure Software

Asure Software provides cloud-based payroll, HR, recruiting, time and attendance, benefits administration and payroll tax management solutions. Its enterprise payroll tax and treasury services support tax filing across jurisdictions, funding and money movement. For more information, visit www.asuresoftware.com.

Use of Forward-Looking Statements

This press release contains certain statements made by management that may constitute “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements about our financial results may include expected or projected U.S GAAP and other operating and non-operating results. The words “believe,” “may,” “will,” “estimate,” “projects,” “anticipate,” “intend,” “expect,” “should,” “plan,” and similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements include statements we make regarding our operating performance, future results of operations and financial position, revenue growth, earnings or other projections. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. The achievement or success of the matters covered by such forward-looking statements involves risks, uncertainties and assumptions, over many of which we have no control. If any such risks or uncertainties materialize or if any of the assumptions prove incorrect, our results could differ materially from the results expressed or implied by the forward-looking statements we make. The risks and uncertainties referred to above include—but are not limited to—risks associated with breaches of our security measures; possible fluctuations in our financial and operating results; potential financing needed to meet future capital requirements; access to additional capital; volatility and weakness in bank and capital markets; the financial and other impact of any previous and future acquisitions; privacy concerns and laws and other regulations that may limit the effectiveness of our applications; inability to adopt new or correctly interpret existing money service and money transmitter business status; risk of our software and solutions not functioning adequately; interruptions, delays or changes in our services or our Web hosting; significant costs as a result of operating as a public company; economic and governmental interruptions to supply chains; risks related to weaknesses in internal control; the inability to continue to release timely updates for changes in laws; the inability to develop new and improved versions of our services and technological developments; customer’s nonrenewal of their agreements and other similar changes; the exposure of market, interest, credit and liquidity risk on client funds held in trust; our operations in highly competitive markets; risks that our clients could have insufficient funds, limitations in the ability to transmit ACH transactions; the nature of our business model; impairment of intangible assets; litigation and any related claims, negotiations and settlements, including with respect to intellectual property matters or industry-specific regulations; market demand of our Software-as-a-Service offerings; adverse effects to our business a result of claims, lawsuits, and other proceedings; adverse material effects caused by advancements and adoption of artificial intelligence; issues in the use of artificial intelligence in our HCM products and services; adverse changes to financial accounting standards to us; intellectual property risks associated with the use of open source software; failures of our service providers; factors affecting our deferred tax assets and ability to value and utilize them; inability to maintain third-party licensed software; evolving regulation of the Internet, changes in the infrastructure underlying the Internet or interruptions in Internet services; the expiration of Employee Retention Tax Credits (“ERTC”) and the impact of recent regulatory and other measures by governmental authorities-regarding ERTC claims and the corresponding cash collections of existing receivables; our ability to hire, retain and motivate employees and manage our growth; potential enactment of adverse tax laws, regulation, political, economic and social factors; potential sales of a substantial number of shares of our common stock along with its volatility; and risks associated with potential equity-related transactions including dividends, rights under the stockholder plan to discourage certain actions and other impacts as a result of actions of our stockholders.

Please review the Company’s risk factors in its annual report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on February 26, 2026.

Investor Relations Contact

Patrick McKillop
Vice President, Investor Relations
617-335-5058
patrick.mckillop@asuresoftware.com

VANCOUVER, British Columbia, Nov. 20, 2026 (GLOBE NEWSWIRE) — HYTN Innovations Inc. (CSE: HYTN) (OTC Pink: HYTNF) (FSE: 85W0) (“HYTN”) and Peptide Development Labs Inc. (CSE: PEPT) (“PEPT”), further to their press release dated November 19, 2026, are pleased to announce that pursuant to a bulletin issued by the Canadian Securities Exchange (the “CSE”) on November 19, 2026, PEPT has now met all final listing requirements of the CSE. Common shares of PEPT (“PEPT Common Shares”) will begin trading on the CSE at market open on November 20, 2026.

Arrangement

Under the statutory plan of arrangement involving HYTN and PEPT (the “Arrangement”), the shareholders of HYTN received PEPT Common Shares by way of a share exchange, pursuant to which each existing share of HYTN held at 12:01 a.m. on November 17, 2026 (a “HYTN Common Share”) was exchanged for one “new” share of HYTN (“New HYTN Common Share”) and 0.0555555555555556 of a PEPT Common Share.

The CSE granted final acceptance of the Arrangement on November 19, 2026. PEPT Common Shares will begin trading on the CSE at market open on November 20, 2026.

Share Reclassification

As part of the Arrangement, HYTN reorganized its authorized share structure effective as at 12:01 a.m. on November 17, 2026 (the “Reclassification”). Under the Reclassification, HYTN’s existing common shares were redesignated as “Class A Common Shares” and a new class of “Class B Common Shares” was created, having rights, privileges, restrictions and conditions identical to those attaching to HYTN’s common shares immediately prior to the Reclassification. Each outstanding Class A Common Share was then exchanged for one Class B Common Share, the Class A Common Shares were cancelled and eliminated from HYTN’s authorized share structure, and the Class B Common Shares were redesignated as “Common Shares”, being the New HYTN Common Shares. Following the Reclassification, HYTN shareholders hold the same number of common shares of HYTN, in the same proportion, as they held immediately prior to the Reclassification.

The Arrangement, which included the Reclassification, was approved by HYTN shareholders at the annual general and special meeting of HYTN held on November 12, 2026. The record date for the Reclassification is November 17, 2026. The New HYTN Common Shares continue to trade on the CSE under the symbol “HYTN” with CUSIP 40443L203 and ISIN CA40443L2030, effective November 17, 2026.

Stock Symbols

New HYTN Common Shares trade on the CSE under HYTN’s current ticker symbol of “HYTN”. The CUSIP number assigned to the New HYTN Common Shares is 40443L203 (ISIN: CA40443L2030).

PEPT Common Shares will trade on the CSE under the ticker symbol “PEPT”. The CUSIP number assigned to the PEPT Common Shares is 713467108 (ISIN: CA7134671089).

About HYTN Innovations Inc.

HYTN formulates, manufactures, markets, and sells premium products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids. HYTN’s mission is to become the top provider of these products in all federally regulated markets. To achieve this, HYTN focuses on identifying market opportunities and quickly bringing its innovative products to market through its elevated development platform.

About Peptide Development Labs Inc.

PEPT is a Canadian pharmaceutical development company focused on advancing investigational peptide-based drug candidates through established regulatory pathways. PEPT’s mission is to develop peptide candidates that may address defined areas of unmet clinical need within a conventional pharmaceutical framework. To achieve this, PEPT focuses on advancing its investigational subcutaneous BPC-157 drug candidate for refractory ligament disorders through GMP-controlled supply, pharmaceutical quality systems, physician-led access, structured data generation and formal clinical development.

For more information contact:
Elliot McKerr
Chief Executive Officer
HYTN Innovations Inc.

or

Fabian Monaco
Chief Executive Officer
Peptide Development Labs Inc.

HYTN Investor Relations:
1.866.590.9289
investments@hytn.life

The CSE has not reviewed, approved, or disapproved the contents of this press release.

Forward-Looking Statements

This press release contains “forward-looking information” within the meaning of applicable Canadian securities laws (collectively, “forward-looking information”). Forward-looking information in this press release includes, but is not limited to, the anticipated commencement of trading of PEPT Common Shares on the CSE.

Forward-looking information is typically identified by the use of words such as “expects”, “intends”, “plans”, “anticipates”, “believes”, “proposes”, “estimates”, “may”, “will”, “should”, “could” or similar expressions, including negative variations thereof, or statements that certain actions, events or results “will”, “may”, “would” or “should” occur or be achieved.

Forward-looking information is based on a number of material factors and assumptions, including, without limitation, that the PEPT Common Shares will commence trading on the CSE within the timeframe currently anticipated.

Although HYTN and PEPT believe that the expectations and assumptions underlying such forward-looking information are reasonable as of the date hereof, such expectations and assumptions may prove to be incorrect, and no assurance can be given that the events anticipated by such forward-looking information will transpire or occur within the timeframes anticipated.

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or events to differ materially from those anticipated in such forward-looking information. Such risks and uncertainties include, without limitation: the risk that PEPT Common Shares do not commence trading on the CSE when anticipated; risks associated with early-stage drug development; regulatory risks, including those relating to clinical development pathways, approvals and compliance requirements; risks relating to reliance on third-party manufacturers, service providers and supply chains; operational and execution risks; intellectual property risks; and general economic, market and financing conditions.

Readers are cautioned that the foregoing list of factors, assumptions and risks is not exhaustive. Additional information regarding the risks and uncertainties applicable to HYTN and PEPT is contained in HYTN’s information circular dated October 16, 2026, and other public disclosure documents available under HYTN and PEPT’s issuer profile on SEDAR+.

The forward-looking information contained in this press release is made as of the date hereof, and HYTN and PEPT undertake no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Readers are cautioned not to place undue reliance on forward-looking information.

  • FDA agrees with plan to pool safety data from four Alzheimer’s and Parkinson’s studies and to integrate it at the level of standardized analysis datasets
  • Safety package will be built in parallel with ongoing studies; NDA submission planned after DUET-AD data readout

MALVERN, Pa., Nov. 20, 2026 (GLOBE NEWSWIRE) —   Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing buntanetap, an investigational once-daily pill for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that the U.S. Food and Drug Administration (FDA) has agreed to the Company’s Integrated Summary of Safety (ISS) plan, including a proposed strategy to pool safety data from its AD and PD clinical studies and to integrate the pooled data at the level of standardized analysis datasets, in support of its planned New Drug Application (NDA) for buntanetap.

The ISS, an essential part of the drug development process, evaluates a drug’s safety in a large number of patients from multiple clinical trials. To build a more robust safety database, Annovis proposed combining data from its AD and PD programs, based on buntanetap’s common mechanism of action, comparable pharmacokinetics, and similar safety profiles in both diseases. The Company also submitted a draft of the data presentation, integration, and calculation.

In addition, FDA agreed with the Company’s proposal to integrate the pooled data at the level of standardized analysis datasets and provided recommendations on the statistical methods for the integrated analysis. Annovis plans to incorporate FDA’s recommendations into its final ISS statistical plan and submit an updated Study Data Standardization Plan.

The pooled analysis will include three randomized, double-blind, placebo-controlled studies and one open-label extension (OLE) study:

  • Completed Phase 3 study in early PD (NCT05357989)
  • Completed Phase 2/3 study in mild to moderate AD (NCT05686044)
  • Active Phase 3 DUET-AD (NCT06709014)
  • Active OLE PD (NCT07284784)

By the 6-month data readout from DUET-AD, Annovis anticipates that over 1,600 participants will have received buntanetap across the pooled studied.

“An NDA has to show not only that a drug works, but that it is safe in a large population treated over a long period,” said Maria Maccecchini, Ph.D., President, Founder and CEO of Annovis. “Because buntanetap acts through the same mechanism in Alzheimer’s and Parkinson’s diseases, FDA’s agreement on pooling and presentation allows us to bring the safety data from both programs together into a single, extensive database. It also means we can build the safety package now, while DUET-AD and OLE PD are still ongoing.”

Annovis intends to submit the NDA following the data readout of DUET-AD.

FDA’s agreement with the pooling strategy does not constitute approval of buntanetap and does not ensure that the NDA will be accepted for filing or approved. FDA will make those determinations based on its review of the complete application, including the efficacy and safety results of DUET-AD.

About Annovis
Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Company’s lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.

Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com

Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com

Company behind the PlantBrain™ Industrial AI Operating System, trusted by large-scale manufacturing, energy and infrastructure operators, adds U.S. market access alongside its Canadian Securities Exchange listing

VANCOUVER, British Columbia, Nov. 20, 2026 (GLOBE NEWSWIRE) — Algo8 AI Inc. (CSE: AIOS) (OTCQB: VIIIF) (“Algo8” or the “Company“), an Industrial Artificial Intelligence company whose PlantBrain™ platform turns industrial data into decisions and actions, is pleased to announce that its common shares have been approved for trading on the OTCQB® Venture Market (“OTCQB“), operated by OTC Markets Group Inc., and will commence trading today under the symbol “VIIIF“.

The Company’s common shares will continue to trade on the Canadian Securities Exchange (the “CSE“) under the symbol “AIOS”. The OTCQB cross-listing is intended to allow U.S. retail and institutional investors to buy and sell Algo8 shares in U.S. dollars, during U.S. market hours, through U.S. brokerage accounts that support OTCQB securities.

Building U.S. Investor Access Behind U.S. Commercial Momentum

The OTCQB listing comes less than six weeks after Algo8 began trading on the CSE on October 13, 2026. It is a deliberate next step in the Company’s capital markets strategy: a significant and growing share of Algo8’s commercial pipeline sits with North American industrial operators, and the OTCQB provides a regulated, transparent venue for the U.S. investors who know those customers best.

Algo8’s Industrial AI Operating System connects the operational and business systems customers already run from plant-floor controllers and historians to MES and ERP and combines industrial context with generative, agentic, predictive and physical AI. The platform has been deployed more than 80 times across large-scale manufacturing, energy and infrastructure operations, where customers use it to optimize production scheduling, maintenance, quality, energy use and throughput. The Company’s investor base includes a strategic investment from Chemelex, a Brookfield portfolio company that is also an Algo8 customer.

“Listing on the OTCQB makes Algo8 more accessible to U.S. investors as we continue to work with U.S. industrial customers, and we believe a U.S. trading presence will increase our visibility with those customers, our channel partners and the institutions that follow the industrial technology space,” said Brandon Kou, President of Algo8.

About Algo8 AI Inc.

Algo8 AI Inc. (CSE: AIOS) (OTCQB: VIIIF) is an Industrial Artificial Intelligence company. Its Industrial AI Operating System, anchored by the flagship PlantBrain™ platform, connects the operational and business systems customers already run and combines industrial context with generative, agentic, predictive and physical AI to turn industrial data into decisions and actions. Large-scale manufacturing, energy and infrastructure operators use it to optimize production scheduling, maintenance, quality, energy use and throughput, driving productivity and progressively more autonomous operations. The platform is delivered to customers globally, from initial diagnostic through deployment and ongoing support.

On behalf of the Board of Directors of Algo8 AI Inc.

Brandon Kou
President and Director

For further information, please contact:

Daniel Gordon
Investor Relations
Phone: 416-827-8761
Email: daniel@adcap.ca
Website: algo8.ai/investors

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States or any other jurisdiction.

Forward-Looking Statements

This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including, without limitation, the anticipated benefits of the OTCQB listing, including increased access for, and visibility and participation among, U.S. investors; the Company’s business strategy, including its capital markets strategy and its expectations regarding its commercial pipeline, U.S. commercial activity and customer growth; the development, deployment and performance of the PlantBrain™ platform and the Company’s Industrial AI Operating System, including anticipated customer outcomes such as improved productivity and more autonomous operations; the expectation that a U.S. trading presence will increase the Company’s visibility with customers, channel partners and institutional investors; and the Company’s ability to execute on its strategic plans and pursue future capital markets initiatives, are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “expects”, “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “will” occur.

Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this news release, including, among other things, market conditions; the benefits of listing on the OTCQB; continued demand for industrial AI solutions among large-scale manufacturing, energy and infrastructure operators; the Company’s ability to convert its commercial pipeline into customer contracts; the Company’s ability to deploy, support and develop its platform; the continuation of its relationships with strategic customers, investors and channel partners; and the Company’s ability to maintain its OTCQB and CSE listings. Although management considers these assumptions to be reasonable, they are inherently subject to significant business, economic, competitive, regulatory and other risks and uncertainties.

These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important risks that may cause actual results to vary include, without limitation, limited or volatile trading and liquidity in the Company’s common shares, including fragmentation of liquidity between the CSE and the OTCQB; the Company’s ability to maintain its OTCQB and CSE listings; the inability of the Company to realize the expected benefits of the OTCQB listing; customer adoption and the conversion of the Company’s commercial pipeline into contracted business; customer concentration and reliance on strategic relationships, including with Chemelex; competition; technological change in AI and industrial automation, and changes in regulation applicable to AI technologies; the availability of financing on acceptable terms; and general market, economic and political conditions, including their effect on the capital spending of industrial customers; and the risks and uncertainties described in the Company’s continuous disclosure filings available under its profile on SEDAR+.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws.

  • Patient samples arrive in Tennessee from UCLA Medical Center, officially kicking off 5,000-participant, multi-center novel registry first announced September 2025
  • Registry program is designed to be incremental, complementary, and symbiotic to iMDx “kitted strategy” and allow clinical community to gain experience using GraftAssure testing technology
  • Study involvement expected to expand access to GraftAssure technology ahead of potential FDA authorization of a kitted form of the clinical assay, currently under review

NASHVILLE, Tenn., Nov. 20, 2026 (GLOBE NEWSWIRE) — Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that the first several patients have been enrolled in its GALACTIC (GraftAssure Lowering Allograft rejeCTIon by Combination) registry study, a prospective, multi-center validation study evaluating GraftAssureTM, the company’s molecular test for monitoring rejection in kidney transplant recipients.

This study serves to introduce GraftAssure technology to new transplant centers and additionally builds validation data ahead of potential FDA authorization of GraftAssureDx, a kitted version of the company’s clinical assay.

“Here at UCLA, we are always interested in innovative research and therefore, we are participating in the GALACTIC Registry, offered by iMDx,” said UCLA Medical Center’s Dr. Suphamai (Michael) Bunnapradist, MD, MS. “Through this registry we will be able to monitor our patients’ transplanted kidney health, initially with a send-out test and ultimately through in-house testing. It is also very exciting to be the center that enrolled the first patient into this national registry.”

iMDx seeks to deliver a best-in-class molecular diagnostic test kit, to expand and improve testing access for kidney transplant patients, which it anticipates will deliver new value in the estimated $3 billion addressable market for regulated transplant rejection testing.

“We are excited to enroll our first patients in the GALACTIC registry study, the goal of which is to gather performance metrics on GraftAssure to guide biopsy and treatment decisions and congratulations to the UCLA team on enrolling the first participants. UCLA played a foundational role in validating donor-derived cell-free DNA for transplant monitoring, and we are pleased to have them help answer an important clinical question: ‘Can GraftAssure better identify patients whose biopsies will confirm rejection?’” iMDx CEO Josh Riggs said. “GALACTIC aims to demonstrate a positive predictive value above 80%, compared with roughly 50% for current assays. Enrollment also allows more transplant teams to gain firsthand experience with GraftAssure.”

Mr. Riggs continued, “We expect that the data from this registry is what payers and clinicians will look to for real-world evidence, and that it will support payer coverage decisions down the line for the family of products using GraftAssure technology.”

About the GALACTIC Registry Study

The GALACTIC registry study is designed as an observational study of iMDx’s GraftAssure clinical assay in kidney transplant patients to build evidence supporting the previously published Combination Model (CM)-Score and relate it to real-world outcomes.

Additionally, iMDx expects that the study will bridge findings directly from its CLIA lab-run GraftAssureCore test to its GraftAssureDx kitted test in development to be run in-house within transplant centers. The study also has a planned ~3-year follow-up period.

About the CM-Score Used with GraftAssure Technology

Through the launch of its study, iMDx is making progress toward driving clinical adoption and building a scientific case for why digital PCR, which is natively quantitative, can enable use cases for dd-cfDNA testing beyond what is currently on the market. To that end, iMDx established a multi-year target of engaging with 50 U.S. transplant centers to evaluate the clinical utility of its combined score.

This combined score, or CM-score, uses two independent measurements of dd-cfDNA, which the company believes improves the clinical performance of dd-cfDNA compared to currently available options. Specifically, the CM-score mathematically combines the relative (percentage, or %) and absolute (copies per milliliter, or cp/mL) measurements of DNA fragments from the transplanted organ, which in this case is the kidney. This data was first presented as late breaking at the World Transplant Congress in August 2025.

In a peer-reviewed study published in the American Journal of Transplantation in June 2026, and as highlighted in a press release issued the same month, the CM-Score demonstrated a positive predictive value of 81%, compared to a 54% published benchmark for single-metric dd-cfDNA measurement, while retaining a high negative predictive value of 91%. This means that there was a tight correlation between the novel GraftAssure CM-score and rejection, and further suggests that the assay is reliably assessing rejection in kidney transplantation versus non-rejection.

The GALACTIC registry is intended to confirm these findings prospectively in real-world clinical use, evaluate their impact on biopsy and immunosuppression management decisions, and generate long-term outcome data. Collection of these data points is intended to support validation as GraftAssure access is expected to expand to new transplant centers upon planned commercialization.

iMDx Transplant Products and Product Candidates in Development

iMDx’s flagship transplant testing technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). The Company’s scientists in Germany and the U.S. have played a critical role over the past decade in developing the science that helped establish dd-cfDNA as a trusted biomarker of transplant rejection. iMDx is commercializing this technology using a market-disruptive business strategy. Under the GraftAssure™ brand, iMDx’s transplant diagnostics include the following:

  • GraftAssureCore – The company’s laboratory-developed test (LDT), currently reimbursed by CMS MolDX at $2,753 per result and performed at iMDx’s CLIA-certified laboratory in Franklin, Tennessee.
  • GraftAssureIQ – A research-use-only (RUO) kit intended and labeled for non-clinical applications.
  • GraftAssureDx – The in vitro diagnostic (IVD) kit currently under FDA review for use in clinical decision-making.

About Insight Molecular Diagnostics, Inc.

Insight Molecular Diagnostics is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. Investors may visit https://investors.imdxinc.com/ for more information.

GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Insight Molecular Diagnostics Inc.

Forward-Looking Statements

Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” “may,” and similar expressions) are forward-looking statements. These statements include those pertaining to, among other things, expected FDA marketing authorization to sell GraftAssureDx,  the GALACTIC Registry (including continued enrollment and anticipated data and results)   the company’s goals to seek a best-in-class molecular diagnostics test kit to expand and improve testing access for kidney transplant patients and deliver new value in the estimated $3 billion addressable market for transplant rejection testing, the clinical utility of the CM-score, transplant and other product candidates in development, and other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management.

Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Insight Molecular Diagnostics’ third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third party reimbursement for patients’ use of any diagnostic tests Insight Molecular Diagnostics or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Insight Molecular Diagnostics, particularly those mentioned in the “Risk Factors” and other cautionary statements found in Insight Molecular Diagnostics’ Securities and Exchange Commission (SEC) filings, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Insight Molecular Diagnostics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. 

FDA
CAUTION: This press release concerns certain products that are under clinical investigation, and which have not yet been cleared or authorized for marketing by the U.S. Food and Drug Administration. These products are currently limited by federal law to investigational use, and no representation is made as to the safety or effectiveness of these products for the purposes for which they are being investigated.

Investor Contact:
Alexandra Grossman
LifeSci Advisors LLC
imdx@lifesciadvisors.com

SANTA ANA, Calif., Nov. 20, 2026 (GLOBE NEWSWIRE) — INVE Technologies, Inc. (NASDAQ: INVE) (“INVE Technologies” or the “Company”) announced today the preliminary results of its modified “Dutch auction” self-tender offer to purchase for cash up to $20 million in value of shares of its common stock, $0.001 par value per share, which expired at 5:00 p.m., New York City time, on Thursday, November 19, 2026.

Based on the preliminary count by Equiniti Trust Company, LLC, the depositary for the tender offer, a total of approximately 10,742,030 shares of the Company’s common stock were properly tendered and not properly withdrawn at or below the purchase price of $2.85 per share, including approximately 828,284 shares that were tendered through notice of guaranteed delivery.

In accordance with the terms and conditions of the tender offer and based on the preliminary count by the depositary, the Company expects to purchase approximately 7,494,734 shares of its common stock at a purchase price of $2.85 per share, for a total cost of approximately $21.4 million, excluding fees and expenses relating to the tender offer. These shares represent approximately 31.4 percent of the Company’s total outstanding shares of common stock as of October 19, 2026. Included in the 7,494,734 shares that the Company expects to purchase are 477,191 shares that the Company has elected to purchase pursuant to its right to purchase up to an additional 2% of its outstanding shares. INVE Technologies has been informed by the depositary that the preliminary proration factor for the shares to be purchased by the Company pursuant to the tender offer is approximately 69.8 percent.

The number of shares expected to be purchased in the tender offer, the purchase price per share and the proration factor are preliminary and subject to change. The preliminary information contained in this press release is subject to confirmation by the depositary and is based on the assumption that all shares tendered through notice of guaranteed delivery will be delivered within the required one trading day period. The final number of shares to be purchased in the tender offer, the final purchase price per share and the final proration factor will be announced following the expiration of the guaranteed delivery period and the completion by the depositary of the confirmation process. Payment for the shares accepted for purchase pursuant to the tender offer, and the return of all other shares tendered and not purchased, will occur promptly following the completion of the confirmation process.

Craig-Hallum Capital Group LLC acted as the exclusive dealer manager for the tender offer. Stockholders who have questions or would like additional information about the tender offer may contact the information agent for the tender offer, D.F. King & Co., Inc., at (800) 515-4507 (toll free) or INVE@dfking.com.

Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements are those involving future events and future results that are based on current expectations as well as the current beliefs and assumptions of management and can be identified by words such as “anticipate,” “believe,” “continue,” “plan,” “will,” “intend,” “expect,” and similar references to the future. Any statement that is not a historical fact, including statements regarding the preliminary results of the tender offer, the preliminary proration factor, the amount, price and the value of shares that the Company expects to purchase in the tender offer and the expectations regarding the consummation of the tender offer is a forward-looking statement. Factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, the risk that the tender offer will not be completed on the terms previously disclosed (including the price range and number of shares that the Company may purchase pursuant to the tender offer), or at all; the risk that the conditions of the tender offer are not satisfied or waived; changes in the determination of the final number of shares to be purchased in the tender offer and the final aggregate purchase price; developments or changes in general economic or market conditions; developments or changes in the securities markets; developments or changes in the Company’s business, financial condition, or cash needs and uses; and the other factors discussed in the Company’s periodic reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, and subsequent reports it files with the SEC. Forward-looking statements are based on information available to the Company as of the date hereof, and the Company undertakes no obligation to publicly update or revise any of these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

INVE Technologies Investor Relations Contact:
IR@invetechnologies.com

VANCOUVER, British Columbia, Nov. 20, 2026 (GLOBE NEWSWIRE) — HYTN Innovations Inc. (CSE: HYTN) (OTC Pink: HYTNF) (FSE: 85W0) (“HYTN”) and Peptide Development Labs Inc. (CSE: PEPT) (“PEPT”), further to their press release dated November 19, 2026, are pleased to announce that pursuant to a bulletin issued by the Canadian Securities Exchange (the “CSE”) on November 19, 2026, PEPT has now met all final listing requirements of the CSE. Common shares of PEPT (“PEPT Common Shares”) will begin trading on the CSE at market open on November 20, 2026.

Arrangement

Under the statutory plan of arrangement involving HYTN and PEPT (the “Arrangement”), the shareholders of HYTN received PEPT Common Shares by way of a share exchange, pursuant to which each existing share of HYTN held at 12:01 a.m. on November 17, 2026 (a “HYTN Common Share”) was exchanged for one “new” share of HYTN (“New HYTN Common Share”) and 0.0555555555555556 of a PEPT Common Share.

The CSE granted final acceptance of the Arrangement on November 19, 2026. PEPT Common Shares will begin trading on the CSE at market open on November 20, 2026.

Share Reclassification

As part of the Arrangement, HYTN reorganized its authorized share structure effective as at 12:01 a.m. on November 17, 2026 (the “Reclassification”). Under the Reclassification, HYTN’s existing common shares were redesignated as “Class A Common Shares” and a new class of “Class B Common Shares” was created, having rights, privileges, restrictions and conditions identical to those attaching to HYTN’s common shares immediately prior to the Reclassification. Each outstanding Class A Common Share was then exchanged for one Class B Common Share, the Class A Common Shares were cancelled and eliminated from HYTN’s authorized share structure, and the Class B Common Shares were redesignated as “Common Shares”, being the New HYTN Common Shares. Following the Reclassification, HYTN shareholders hold the same number of common shares of HYTN, in the same proportion, as they held immediately prior to the Reclassification.

The Arrangement, which included the Reclassification, was approved by HYTN shareholders at the annual general and special meeting of HYTN held on November 12, 2026. The record date for the Reclassification is November 17, 2026. The New HYTN Common Shares continue to trade on the CSE under the symbol “HYTN” with CUSIP 40443L203 and ISIN CA40443L2030, effective November 17, 2026.

Stock Symbols

New HYTN Common Shares trade on the CSE under HYTN’s current ticker symbol of “HYTN”. The CUSIP number assigned to the New HYTN Common Shares is 40443L203 (ISIN: CA40443L2030).

PEPT Common Shares will trade on the CSE under the ticker symbol “PEPT”. The CUSIP number assigned to the PEPT Common Shares is 713467108 (ISIN: CA7134671089).

About HYTN Innovations Inc.

HYTN formulates, manufactures, markets, and sells premium products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids. HYTN’s mission is to become the top provider of these products in all federally regulated markets. To achieve this, HYTN focuses on identifying market opportunities and quickly bringing its innovative products to market through its elevated development platform.

About Peptide Development Labs Inc.

PEPT is a Canadian pharmaceutical development company focused on advancing investigational peptide-based drug candidates through established regulatory pathways. PEPT’s mission is to develop peptide candidates that may address defined areas of unmet clinical need within a conventional pharmaceutical framework. To achieve this, PEPT focuses on advancing its investigational subcutaneous BPC-157 drug candidate for refractory ligament disorders through GMP-controlled supply, pharmaceutical quality systems, physician-led access, structured data generation and formal clinical development.

For more information contact:
Elliot McKerr
Chief Executive Officer
HYTN Innovations Inc.

or

Fabian Monaco
Chief Executive Officer
Peptide Development Labs Inc.

HYTN Investor Relations:
1.866.590.9289
investments@hytn.life

The CSE has not reviewed, approved, or disapproved the contents of this press release.

Forward-Looking Statements

This press release contains “forward-looking information” within the meaning of applicable Canadian securities laws (collectively, “forward-looking information”). Forward-looking information in this press release includes, but is not limited to, the anticipated commencement of trading of PEPT Common Shares on the CSE.

Forward-looking information is typically identified by the use of words such as “expects”, “intends”, “plans”, “anticipates”, “believes”, “proposes”, “estimates”, “may”, “will”, “should”, “could” or similar expressions, including negative variations thereof, or statements that certain actions, events or results “will”, “may”, “would” or “should” occur or be achieved.

Forward-looking information is based on a number of material factors and assumptions, including, without limitation, that the PEPT Common Shares will commence trading on the CSE within the timeframe currently anticipated.

Although HYTN and PEPT believe that the expectations and assumptions underlying such forward-looking information are reasonable as of the date hereof, such expectations and assumptions may prove to be incorrect, and no assurance can be given that the events anticipated by such forward-looking information will transpire or occur within the timeframes anticipated.

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or events to differ materially from those anticipated in such forward-looking information. Such risks and uncertainties include, without limitation: the risk that PEPT Common Shares do not commence trading on the CSE when anticipated; risks associated with early-stage drug development; regulatory risks, including those relating to clinical development pathways, approvals and compliance requirements; risks relating to reliance on third-party manufacturers, service providers and supply chains; operational and execution risks; intellectual property risks; and general economic, market and financing conditions.

Readers are cautioned that the foregoing list of factors, assumptions and risks is not exhaustive. Additional information regarding the risks and uncertainties applicable to HYTN and PEPT is contained in HYTN’s information circular dated October 16, 2026, and other public disclosure documents available under HYTN and PEPT’s issuer profile on SEDAR+.

The forward-looking information contained in this press release is made as of the date hereof, and HYTN and PEPT undertake no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Readers are cautioned not to place undue reliance on forward-looking information.

Combined company renamed Vesicor Therapeutics Holdings, Inc.; common stock expected to begin trading on Nasdaq under the ticker symbol “VESI” on November 23, 2026

SAN GABRIEL, Calif., Nov. 20, 2026 (GLOBE NEWSWIRE) — Vesicor Therapeutics Holdings, Inc. (“Vesicor” or the “Company”), an early development stage biotechnology company focused on the development of p53-based cancer therapeutics delivered via precision-engineered microvesicles, today announced the closing of its previously announced business combination with Black Hawk Acquisition Corporation (Nasdaq: BKHA) (“Black Hawk”). The transaction was approved by Black Hawk’s shareholders at an extraordinary general meeting held on October 13, 2026 and closed on November 19, 2026. In connection with the closing, Black Hawk domesticated from the Cayman Islands to Delaware and changed its name to Vesicor Therapeutics Holdings, Inc. The Company’s common stock is expected to begin trading on the Nasdaq Capital Market under the ticker symbol “VESI” on November 23, 2026.

Vesicor will be led by Michael Tolentino, MD, Chief Executive Officer; Luo Feng, PhD, Founder, Director and Chief Scientific Officer; Mitch Creem, MHA, Chief Financial Officer; and Warren Hosseinion, Jr., Chief Operating Officer. The Company’s Board of Directors consists of Warren Hosseinion, Sr., MD (Chairman), Luo Feng, PhD, Oded Levy, Frederick Woodruff Field and Qi Ouyang.

“Closing this transaction gives Vesicor access to the public markets at the point where the Company needs it most, as we prepare to begin IND-enabling studies for ecm-RV/p53,” said Warren Hosseinion, Sr., MD, Chairman of the Board. “I want to thank our shareholders and the Vesicor team for the work that brought us here. Our focus now is execution.”

“I founded Vesicor in 2008 with the goal of developing p53-based cancer therapeutics using precision-engineered microvesicles,” said Luo Feng, PhD, Founder, Director and Chief Scientific Officer. “ecm-RV/p53 reflects many years of research, and we are focused on building on that foundation as we seek to advance the program toward clinical evaluation.”

“Our priority as a public company is clear: advance ecm-RV/p53 through IND-enabling studies and toward an IND submission to the FDA,” said Michael Tolentino, MD, Chief Executive Officer. “We have a defined goal, an experienced team and a board that has the skills to advance the priorities of the Company. We look forward to reporting our progress to shareholders.”

Advisors

Celine & Partners, P.L.L.C. and Ogier Global (Cayman) Limited served as legal counsel to Black Hawk. D. Boral Capital LLC served as the capital markets advisor to Black Hawk. PW Richter PLC, Winston Taylor LLP, and Shartsis Friese LLP served as legal counsel to Vesicor.

About Vesicor Therapeutics

Vesicor Therapeutics Holdings, Inc. is an early development stage biotechnology company focused on the development of p53-based cancer therapeutics delivered via precision-engineered microvesicles. The Company’s product candidate, ecm-RV/p53, is being advanced toward IND-enabling studies and an Investigational New Drug application with the U.S. Food and Drug Administration. Founded in 2008, Vesicor is headquartered in San Gabriel, California. For more information, visit [www.vesicor.com].

About Black Hawk Acquisition Corporation

Black Hawk Acquisition Corporation was a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Black Hawk completed its initial public offering in March 2024 and its ordinary shares, rights and units were listed on Nasdaq under the symbols “BKHA,” “BKHAR” and “BKHAU.”

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding the expected trading of the Company’s common stock on Nasdaq, the Company’s plans to conduct preclinical and IND-enabling studies and to submit an IND for ecm-RV/p53, the potential approval of the Company’s sole product candidate, the therapeutic potential of ecm-RV/p53, and the Company’s strategy, plans and objectives. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including: the Company has not commenced preclinical and IND-enabling studies or filed an IND, and may not receive regulatory approval for clinical trials for ecm-RV/p53; ecm-RV/p53 is the Company’s sole product candidate; uncertainty regarding the outcomes of any preclinical studies or clinical trials; the Company’s need for additional capital; the Company’s ability to maintain the listing of its common stock on Nasdaq; and the other risks described under “Risk Factors” in the definitive proxy statement/prospectus filed by Black Hawk with the Securities and Exchange Commission on September 22, 2026 and in the Company’s subsequent filings with the SEC. Forward-looking statements speak only as of the date of this release, and the Company undertakes no obligation to update them except as required by law.

Contact
Warren Hosseinion Jr.
warrenjr@vesicor.com

SHENZHEN, China, Nov. 20, 2026 (GLOBE NEWSWIRE) — ZJK Industrial Co., Ltd. (NASDAQ: ZJK) (“ZJK” or the “Company”), a high-tech precision parts and hardware manufacturer serving artificial intelligence (AI) infrastructure, consumer electronics, electric vehicles, aerospace, and other smart technologies, today announced key operational progress in its aerospace precision fastener business of obtaining EN9100:2018 certification.

After meeting stringent aerospace standards for structural reliability and precision, ZJK’s subsidiary, ZhongKe Precision Components (Guangdong) Co. Ltd. (“Guangdong Subsidiary”), has obtained a certification of its aerospace quality management system under EN 9100:2018, a standard technically equivalent to AS 9100D and JISQ 9100:2016. Guangdong Subsidiary has established an end-to-end technical system across material selection, process design, precision machining, inspection, and validation. Leveraging its expertise in high-performance materials, including titanium alloys and superalloys, ZJK has made progress in relevant customer validation and related supply processes, laying a solid foundation for future volume ramp-up. The resources of Guangdong Subsidiary can also be drawn on to support ZJK’s Sichuan manufacturing base in aerospace manufacturing.

ZJK’s management stated, “Aerospace represents an attractive growth opportunity alongside our AI infrastructure business. Rigorous qualification standards create high entry barriers in aerospace fasteners. With EN 9100-certified capabilities in Guangdong and expertise in high-performance materials, we are well equipped to deepen customer collaborations and pursue future opportunities across the commercial space and low-altitude aviation markets.”

About ZJK Industrial Co., Ltd.

ZJK Industrial Co., Ltd. (NASDAQ: ZJK) is a high-tech precision parts and hardware manufacturer serving artificial intelligence (AI) infrastructure, consumer electronics, electric vehicles, aerospace, and other smart technologies. With over 15 years in the precision metal parts manufacturing industry, the Company maintains a skilled engineering team, highly automated CNC and precision manufacturing equipment, a diversified global customer base, and comprehensive quality management systems. ZJK mainly offers precision screws and nuts, high-strength bolts, turning and stamping parts, CNC machining and milling parts, high-precision structural components, and miniature Surface Mounting Technology (SMT) packaging. For more information, please visit https://ir.zjk-industrial.com/.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These statements include the Company’s plans to expand its aerospace fastener business, pursue opportunities in commercial space and low-altitude aviation, and develop aerospace applications as a source of future growth. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Relevant risks and uncertainties include the Company’s ability to satisfy customer qualification requirements, secure aerospace customer orders, and successfully expand production, as well as other factors described in the Company’s filings with the U.S. Securities and Exchange Commission. Investors can find many (but not all) of these statements by the use of words such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “likely to,” “propose,” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements except as may be required by law.

For more information, please contact:
ZJK Industrial Co., Ltd.
Phone: +86-755-28341175
Email: ir@zjk-industrial.com

The Blueshirt Group Asia
Feifei Shen
Phone: +86-134-66566136
Email: feifei@blueshirtgroup.co

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.